PAK proteins and YAP-1 signalling downstream of integrin beta-1 in myofibroblasts promote liver fibrosis

Nature Communications

Volumn 7, Issue , 2016, Pages

  Martin, Katherine ^a,b   Pritchett, James ^a,b   Llewellyn, Jessica ^a   Mullan, Aoibheann F ^a   Athwal, Varinder S ^a,b   Dobie, Ross ^c   Harvey, Emma ^a   Zeef, Leo ^d   Farrow, Stuart ^a,e   Streuli, Charles ^f   Henderson, Neil C ^c   Friedman, Scott L ^g   Hanley, Neil A ^a,b   Hanley, Karen Piper ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e GLAXOSMITHKLINE   (United Kingdom)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BETA1 INTEGRIN; P21 ACTIVATED KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; TRANSCRIPTION FACTOR YAP1; MYOSIN LIGHT CHAIN; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

CELLS AND CELL COMPONENTS; ENZYME; GENE; GENE EXPRESSION; INHIBITION; PHENOTYPE; PHYSIOLOGY; PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CELL ACTIVATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER FIBROSIS; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; PHENOTYPE; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; C57BL MOUSE; HEPATIC STELLATE CELL; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; HEPATIC STELLATE CELLS; HUMANS; INTEGRIN BETA1; LIVER CIRRHOSIS; MALE; MICE, INBRED C57BL; MYOFIBROBLASTS; MYOSIN LIGHT CHAINS; P21-ACTIVATED KINASES; PHENOTYPE; PHOSPHOPROTEINS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION;

EID: 84983326095     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12502     Document Type: Article

References (45)

1. Poynard, T. et al. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol. 10, 40 (2010).
2. Mokdad, A. A. et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: A systematic analysis. BMC. Med. 12, 145 (2014).
3. Ellis, E. L. & Mann, D. A. Clinical evidence for the regression of liver fibrosis. J. Hepatol. 56, 1171-1180.
4. Kisseleva, T. et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc. Natl Acad. Sci. USA 109, 9448-9453 (2012).
5. Troeger, J. S. et al. Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. Gastroenterology 143, 1073-1083 e1022 (2012).
6. Cohen-Naftaly, M. & Friedman, S. L. Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap. Adv. Gastroenterol. 4, 391-417 (2011).
7. Friedman, S. L., Sheppard, D., Duffield, J. S. & Violette, S. Therapy for fibrotic diseases: nearing the starting line. Sci. Transl. Med. 5, 167sr161 (2013).
8. Friedman, S. L., Roll, F. J., Boyles, J. & Bissell, D. M. Hepatic lipocytes: The principal collagen-producing cells of normal rat liver. Proc. Natl Acad. Sci. USA 82, 8681-8685 (1985).
9. Mederacke, I. et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat. Commun. 4, 2823 (2013).
10. Hanley, K. P. et al. Ectopic SOX9 mediates extracellular matrix deposition characteristic of organ fibrosis. J. Biol. Chem. 283, 14063-14071 (2008).
11. Pritchett, J. et al. Osteopontin is a novel downstream target of SOX9 with diagnostic implications for progression of liver fibrosis in humans. Hepatology 56, 1108-1116 (2012).
12. Lee, Y. A., Wallace, M. C. & Friedman, S. L. Pathobiology of liver fibrosis: A translational success story. Gut 64, 830-841 (2015).
13. Dupont, S. et al. Role of YAP/TAZ in mechanotransduction. Nature 474, 179-183 (2011).
14. Mannaerts, I. et al. The Hippo pathway effector YAP controls mouse hepatic stellate cell activation. J. Hepatol. 63, 679-688 (2015).
15. Hynes, R. O. Integrins: bidirectional, allosteric signaling machines. Cell 110, 673-687 (2002).
16. Henderson, N. C. & Sheppard, D. Integrin-mediated regulation of TGFbeta in fibrosis. Biochim. Biophys. Acta 1832, 891-896 (2013).
17. Racine-Samson, L., Rockey, D. C. & Bissell, D. M. The role of alpha1beta1 integrin in wound contraction. A quantitative analysis of liver myofibroblasts in vivo and in primary culture. J. Biol. Chem. 272, 30911-30917 (1997)
18. Henderson, N. C. et al. Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat. Med. 19, 1617-1624 (2013).
19. Liu, S. et al. Expression of integrin beta1 by fibroblasts is required for tissue repair in vivo. J. Cell. Sci. 123, 3674-3682 (2010).
20. Pritchett, J. et al. Epimorphin alters the inhibitory effects of SOX9 on Mmp13 in activated hepatic stellate cells. PLoS One 9, e100091 (2014).
21. Jeanes, A. I. et al. Specific beta-containing integrins exert differential control on proliferation and two-dimensional collective cell migration in mammary epithelial cells. J. Biol. Chem. 287, 24103-24112 (2012).
22. Iwamoto, H., Sakai, H., Tada, S., Nakamuta, M. & Nawata, H. Induction of apoptosis in rat hepatic stellate cells by disruption of integrin-mediated cell adhesion. J. Lab. Clin. Med. 134, 83-89 (1999).
23. Nguyen, H. T. et al. Viral small T oncoproteins transform cells by alleviating hippo-pathway-mediated inhibition of the YAP proto-oncogene. Cell Rep. 8, 707-713 (2014).
24. Calvo, F. et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-Associated fibroblasts. Nat. Cell. Biol. 15, 637-646 (2013).
25. Bandapalli, O. R., Macher-Goeppinger, S., Schirmacher, P. & Brand, K. Paracrine signalling in colorectal liver metastases involving tumor cell-derived PDGF-C and hepatic stellate cell-derived PAK-2. Clin. Exp. Metastasis. 29, 409-417 (2012).
26. Rovida, E., Navari, N., Caligiuri, A., Dello Sbarba, P. & Marra, F. ERK5 differentially regulates PDGF-induced proliferation and migration of hepatic stellate cells. J. Hepatol. 48, 107-115 (2008).
27. Liu-Chittenden, Y. et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 26, 1300-1305 (2012).
28. Zhao, B. et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 22, 1962-1971 (2008).
29. Paradis, V. et al. Effects and regulation of connective tissue growth factor on hepatic stellate cells. Lab. Invest. 82, 767-774 (2002).
30. Williams, E. J., Gaca, M. D., Brigstock, D. R., Arthur, M. J. & Benyon, R. C. Increased expression of connective tissue growth factor in fibrotic human liver and in activated hepatic stellate cells. J. Hepatol. 32, 754-761 (2000).
31. Kichina, J. V., Goc, A., Al-Husein, B., Somanath, P. R. & Kandel, E. S. PAK1 as a therapeutic target. Exp. Opin. Ther. Targets 14, 703-725 (2010).
32. Deacon, S. W. et al. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-Activated kinase. Chem. Biol. 15, 322-331 (2008).
33. De Minicis, S. et al. Gene expression profiles during hepatic stellate cell activation in culture and in vivo. Gastroenterology 132, 1937-1946 (2007):
34. Mederacke, I., Dapito, D. H., Affo, S., Uchinami, H. & Schwabe, R. F. Highyield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse livers. Nat. Protoc. 10, 305-315 (2015).
35. Navab, R. et al. Integrin alpha11beta1 regulates cancer stromal stiffness and promotes tumorigenicity and metastasis in non-small cell lung cancer. Oncogene 35, 1899-1908 (2015).
36. Talior-Volodarsky, I., Connelly, K. A., Arora, P. D., Gullberg, D. & McCulloch, C. A. alpha11 integrin stimulates myofibroblast differentiation in diabetic cardiomyopathy. Cardiovasc. Res. 96, 265-275 (2012).
37. Zhao, B. et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 21, 2747-2761 (2007).
38. Coniglio, S. J., Zavarella, S. & Symons, M. H. Pak1 and Pak2 mediate tumor cell invasion through distinct signaling mechanisms. Mol. Cell. Biol. 28, 4162-4172 (2008).
39. Bright, M. D., Garner, A. P. & Ridley, A. J. PAK1 and PAK2 have different roles in HGF-induced morphological responses. Cell. Signal. 21, 1738-1747 (2009).
40. Radu, M., Semenova, G., Kosoff, R. & Chernoff, J. PAK signalling during the development and progression of cancer. Nat. Rev. Cancer 14, 13-25 (2014).
41. Khare, V. et al. Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1. Biochem. Pharmacol. 85, 234-244 (2013).
42. Oakley, F. et al. Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. Gastroenterology 128, 108-120 (2005).
43. Friedman, S. L. et al. Isolated hepatic lipocytes and Kupffer cells from normal human liver: morphological and functional characteristics in primary culture. Hepatology 15, 234-243 (1992).
44. Xu, L. et al. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 54, 142-151 (2005).
45. Levy, D., Adamovich, Y., Reuven, N. & Shaul, Y. Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage. Mol. Cell. 29, 350-361 (2008).